annual CFF:
$457.74M+$232.07M(+102.83%)Summary
- As of today (September 19, 2025), VRDN annual cash flow from financing activities is $457.74 million, with the most recent change of +$232.07 million (+102.83%) on December 31, 2024.
- During the last 3 years, VRDN annual CFF has risen by +$332.46 million (+265.39%).
- VRDN annual CFF is now at all-time high.
Performance
VRDN Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$764.00K-$8.45M(-91.71%)Summary
- As of today (September 19, 2025), VRDN quarterly cash flow from financing activities is $764.00 thousand, with the most recent change of -$8.45 million (-91.71%) on June 30, 2025.
- Over the past year, VRDN quarterly CFF has increased by +$656.00 thousand (+607.41%).
- VRDN quarterly CFF is now -99.69% below its all-time high of $245.02 million, reached on September 30, 2024.
Performance
VRDN quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$290.52M+$656.00K(+0.23%)Summary
- As of today (September 19, 2025), VRDN TTM cash flow from financing activities is $290.52 million, with the most recent change of +$656.00 thousand (+0.23%) on June 30, 2025.
- Over the past year, VRDN TTM CFF has dropped by -$101.06 million (-25.81%).
- VRDN TTM CFF is now -53.23% below its all-time high of $621.15 million, reached on September 30, 2024.
Performance
VRDN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
VRDN Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +102.8% | +607.4% | -25.8% |
| 3 y3 years | +265.4% | -83.2% | +137.6% |
| 5 y5 years | +10000.0% | -39.8% | +1439.3% |
VRDN Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +265.4% | -99.7% | +607.4% | -53.2% | +2477.4% |
| 5 y | 5-year | at high | >+9999.0% | -99.7% | +607.4% | -53.2% | +2477.4% |
| alltime | all time | at high | >+9999.0% | -99.7% | +184.5% | -53.2% | >+9999.0% |
VRDN Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $764.00K(-91.7%) | $290.52M(+0.2%) |
| Mar 2025 | - | $9.21M(-74.1%) | $289.87M(-36.7%) |
| Dec 2024 | $457.74M(+102.8%) | $35.52M(-85.5%) | $457.74M(-26.3%) |
| Sep 2024 | - | $245.02M(>+9900.0%) | $621.15M(+58.6%) |
| Jun 2024 | - | $108.00K(-99.9%) | $391.59M(-0.8%) |
| Mar 2024 | - | $177.08M(-11.0%) | $394.55M(+74.8%) |
| Dec 2023 | $225.67M(-30.0%) | $198.94M(+1187.1%) | $225.67M(+744.3%) |
| Sep 2023 | - | $15.46M(+403.8%) | $26.73M(+137.1%) |
| Jun 2023 | - | $3.07M(-62.6%) | $11.27M(-11.7%) |
| Mar 2023 | - | $8.20M(+80.0%) | $12.76M(-89.6%) |
| Dec 2022 | $322.24M(+157.2%) | - | - |
| Jun 2022 | - | $4.56M(+517.6%) | $122.26M(-2.0%) |
| Mar 2022 | - | $738.00K(+334.1%) | $124.75M(-0.4%) |
| Dec 2021 | $125.28M(+23.7%) | $170.00K(-99.9%) | $125.28M(-38.2%) |
| Sep 2021 | - | $116.79M(+1556.2%) | $202.79M(+123.7%) |
| Jun 2021 | - | $7.05M(+460.1%) | $90.64M(+6.8%) |
| Mar 2021 | - | $1.26M(-98.4%) | $84.86M(-16.2%) |
| Dec 2020 | $101.31M(>+9900.0%) | $77.68M(+1572.4%) | $101.31M(+314.8%) |
| Sep 2020 | - | $4.64M(+266.3%) | $24.42M(+29.4%) |
| Jun 2020 | - | $1.27M(-92.8%) | $18.87M(+7.4%) |
| Mar 2020 | - | $17.71M(+2128.3%) | $17.57M(>+9900.0%) |
| Dec 2019 | $70.00K | $795.00K(-187.9%) | $70.00K(-109.5%) |
| Sep 2019 | - | -$904.00K(+2217.9%) | -$735.00K(-157.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | -$39.00K(-117.9%) | $1.28M(-68.1%) |
| Mar 2019 | - | $218.00K(-2280.0%) | $4.02M(-90.4%) |
| Dec 2018 | $41.92M(-20.1%) | -$10.00K(-100.9%) | $41.92M(-22.1%) |
| Sep 2018 | - | $1.11M(-58.7%) | $53.84M(-2.0%) |
| Jun 2018 | - | $2.70M(-92.9%) | $54.92M(+6.7%) |
| Mar 2018 | - | $38.11M(+219.9%) | $51.47M(-1.9%) |
| Dec 2017 | $52.47M(<-9900.0%) | $11.91M(+442.5%) | $52.47M(+30.0%) |
| Sep 2017 | - | $2.20M(-390.9%) | $40.35M(-25.7%) |
| Jun 2017 | - | -$755.00K(-101.9%) | $54.33M(-1.3%) |
| Mar 2017 | - | $39.12M(<-9900.0%) | $55.04M(+246.7%) |
| Dec 2016 | -$257.00K(-102.0%) | -$207.00K(-101.3%) | $15.87M(-1.2%) |
| Sep 2016 | - | $16.18M(<-9900.0%) | $16.06M(+315.4%) |
| Jun 2016 | - | -$51.00K(+8.5%) | $3.87M(+16.9%) |
| Mar 2016 | - | -$47.00K(+135.0%) | $3.31M(-73.9%) |
| Dec 2015 | $12.71M(+71.8%) | -$20.00K(-100.5%) | $12.66M(-0.1%) |
| Sep 2015 | - | $3.98M(-753.1%) | $12.67M(+54.2%) |
| Jun 2015 | - | -$610.00K(-106.6%) | $8.21M(-6.9%) |
| Mar 2015 | - | $9.30M(<-9900.0%) | $8.82M(-1939.9%) |
| Dec 2014 | $7.40M(+487.5%) | -$10.90K(-97.7%) | -$479.50K(+282.7%) |
| Sep 2014 | - | -$468.60K(-236.5%) | -$125.30K(-136.5%) |
| Dec 2013 | $1.26M(-78.3%) | $343.30K(-1244.3%) | $343.30K(-1244.3%) |
| Dec 2012 | $5.81M | - | - |
| Dec 2012 | - | -$30.00K | -$30.00K |
FAQ
- What is Viridian Therapeutics, Inc. annual cash flow from financing activities?
- What is the all time high annual CFF for Viridian Therapeutics, Inc.?
- What is Viridian Therapeutics, Inc. annual CFF year-on-year change?
- What is Viridian Therapeutics, Inc. quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Viridian Therapeutics, Inc.?
- What is Viridian Therapeutics, Inc. quarterly CFF year-on-year change?
- What is Viridian Therapeutics, Inc. TTM cash flow from financing activities?
- What is the all time high TTM CFF for Viridian Therapeutics, Inc.?
- What is Viridian Therapeutics, Inc. TTM CFF year-on-year change?
What is Viridian Therapeutics, Inc. annual cash flow from financing activities?
The current annual CFF of VRDN is $457.74M
What is the all time high annual CFF for Viridian Therapeutics, Inc.?
Viridian Therapeutics, Inc. all-time high annual cash flow from financing activities is $457.74M
What is Viridian Therapeutics, Inc. annual CFF year-on-year change?
Over the past year, VRDN annual cash flow from financing activities has changed by +$232.07M (+102.83%)
What is Viridian Therapeutics, Inc. quarterly cash flow from financing activities?
The current quarterly CFF of VRDN is $764.00K
What is the all time high quarterly CFF for Viridian Therapeutics, Inc.?
Viridian Therapeutics, Inc. all-time high quarterly cash flow from financing activities is $245.02M
What is Viridian Therapeutics, Inc. quarterly CFF year-on-year change?
Over the past year, VRDN quarterly cash flow from financing activities has changed by +$656.00K (+607.41%)
What is Viridian Therapeutics, Inc. TTM cash flow from financing activities?
The current TTM CFF of VRDN is $290.52M
What is the all time high TTM CFF for Viridian Therapeutics, Inc.?
Viridian Therapeutics, Inc. all-time high TTM cash flow from financing activities is $621.15M
What is Viridian Therapeutics, Inc. TTM CFF year-on-year change?
Over the past year, VRDN TTM cash flow from financing activities has changed by -$101.06M (-25.81%)